Patent · US Active

Pharmaceutical compositions comprising (2S)-n-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide

US12201638B2 · kind B2 · utility

0Cited by

32References

8Claims

0Family size

Assignee

ASTRAZENECA AB · SE

Inventors

Hakan V. Wikstrom · Mölndal, SE
Jufang Wu LUDVIGSSON · Mölndal, SE
Thomas Andersson · Eskilstuna, SE

Key dates

Filing date	Mar 28, 2024
Grant date	Jan 21, 2025
Priority date	—
Expiry date	Mar 28, 2044

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K16/2887
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (Compound A) or a pharmaceutically acceptable salt thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.